Ontada’s Clear Value Plus Provides 800,000th Chemotherapy Treatment Decision

Most used oncology pathway technology solution enables evidence-based decisions and accelerates prior authorization, resulting in smarter, quicker patient treatment

IRVING, TEXAS–(BUSINESS WIRE)–#ehr—Ontada^TM, McKesson’s oncology technology and insights business, recently reached a major milestone by providing its 800,000^th evidence-based treatment option through Clear Value Plus^SM. As the #1 most-used oncology pathway by medical oncologists, Clear Value Plus is relied on by more than 2,400 providers to deliver high-quality cancer care. The application provides evidence-based treatment options, while reducing the burden of prior authorizations and increasing financial transparency for patients. The content in Clear Value Plus is consistently updated within two days of new guideline releases, ensuring that providers reliably have access to the most up-to-date evidence-based care options available.

“With roots that extend decades in community oncology, Ontada’s technologies, including Clear Value Plus, continue to help providers fulfill their mission of bringing the best possible care to their patients,” said Steve Beier, vice president and general manager of technology solutions, Ontada. “Every single one of the 800,000 regimen recommendations in Clear Value has enabled an oncology provider to deliver evidence-based care at the point of need for their patient to give them the right therapy at the right time.”

Clear Value Plus allows providers to participate in value-based care programs by confirming their chosen therapies are consistent with nationally recognized clinical guidelines, like NCCN Practice Guidelines in Clinical Oncology^® and Value Pathways powered by NCCN^TM, to meet the requirements of the Oncology Care Model (OCM) and the Merit-based Incentive Payment System (MIPS) Improvement Activities category.

“Cancer treatment choices are improving and updating rapidly, so providing access to evidence-based treatment recommendations at the point of care is a big assist to oncologists,” said Marcus Neubauer, MD, chief medical officer, The US Oncology Network. “High-quality care is a top priority for oncologists, and Clear Value Plus displays the best treatment options based on the latest evidence and clinical trial results.”

The US Oncology Network (The Network), supported by McKesson, is one of the largest networks of independent, community-based oncologists dedicated to advancing local cancer care and delivering better patient outcomes. More than 800 physicians in The Network utilize Clear Value Plus.

Part of Ontada’s full suite of technology solutions, Clear Value Plus automatically records treatment decisions in the patient record of the practice’s integrated electronic health record (EHR) system, including Ontada’s iKnowMed^SM. By leveraging integrated technology solutions, oncology providers are empowered to determine the best treatment alternative at the patient’s point of need.

About Ontada

Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients’ lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and power the future of cancer care. For more information, visit ontada.com or follow @OntadaOncology.

About The US Oncology Network

Every day, The US Oncology Network (The Network) helps more than 1,380 independent physicians deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure and support of McKesson Corporation. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.

Contacts

General and Business Press

Ontada

Annabelle Baxter, External Communications

T 469.233.3400 annabelle.baxter@mckesson.com

The US Oncology Network

Claire Crye, Public Relations

T 281.825.9927 claire.crye@usoncology.com